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Mutations in DARS Cause Hypomyelination with Brain Stem
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Inherited white-matter disorders are a broad class of diseases for which treatment and classification are both challenging. Indeed, nearly
half of the children presenting with a leukoencephalopathy remain without a specific diagnosis. Here, we report on the application of
high-throughput genome and exome sequencing to a cohort of ten individuals with a leukoencephalopathy of unknown etiology and
clinically characterized by hypomyelination with brain stem and spinal cord involvement and leg spasticity (HBSL), as well as the
identification of compound-heterozygous and homozygous mutations in cytoplasmic aspartyl-tRNA synthetase (DARS). These muta-
tions cause nonsynonymous changes to seven highly conserved amino acids, five of which are unchanged between yeast and man,
in the DARS C-terminal lobe adjacent to, or within, the active-site pocket. Intriguingly, HBSL bears a striking resemblance to
leukoencephalopathy with brain stem and spinal cord involvement and elevated lactate (LBSL), which is caused by mutations in the
mitochondria-specific DARS2, suggesting that these two diseases might share a common underlying molecular pathology. These
findings add to the growing body of evidence that mutations in tRNA synthetases can cause a broad range of neurologic disorders.As recognized more than a decade ago, nearly half of
childhood leukoencephalopathies remain unclassified
and are a diagnostic problem for pediatric neurologists
and neuroradiologists.1 Many of these disorders are
extremely rare, precluding conventional genetic linkage
studies, but they are potentially amenable to whole-
genome sequencing (WGS) or whole-exome sequencing
(WES) analysis, particularly if unaffected family members
are available and affected individuals can be nosologically
clustered with MRI pattern recognition.1,2
The first child examined in this study, subject 1
(Figure 1), was diagnosed with a tethered cord as a
newborn and subsequently developed global develop-
mental delay and severe leg spasticity (for clinical details,
see Table S1, available online); extensive white-matter
abnormalities involved the supratentorial brain white
matter, brain stem, and spinal cord (Figure 1 and
Table S2). A comprehensive panel of imaging, metabolic,
and genetic studies failed to yield a definitive diagnosis,
and he was subsequently enrolled in an ongoing study
investigating the etiology of unclassified neurological
disorders at the Murdoch Children’s Research Institute1Institute for Molecular Bioscience, University of Queensland, St. Lucia, Qu
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Research Ethics Committee [HREC reference number
28097], and informed consent was obtained from all
participating individuals). WGS was performed on the
affected proband and both parents (approved by the
University of Queensland Ethics Office, projects
2012000375 and 2012000376). Sequencing reads were
aligned to the reference human genome (UCSC Genome
Browser hg19) with the Burrows-Wheeler Aligner,3 and
downstream processing was carried out with a pipeline
composed of the Genome Analysis Toolkit,4,5 SAMtools,6
Picard (see Web Resources), Annovar,7 and a set of custom
analysis and visualization tools. Average genome coverage
for this family exceeded 383 (Table S3), which yielded
more than 3.2 million variants per genome. A custom-
developed differential family-trio analysis yielded a single
likely candidate gene—DARS (MIM 603084, RefSeq acces-
sion number NM_001349.2), encoding an aspartyl-tRNA
synthetase (AspRS). In this gene, we found a compound-
heterozygous mutation, c.1099G>T (p.Asp376Tyr)
(paternal allele) and c.821C>T (p.Ala274Val) (maternal
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Figure 1. MRI Patterns Characteristic
of HBSL
MRI images of subjects 1, 2 and 4: (A), (B),
and (D)–(L) show axial T2-weighted
images, and (C) shows a sagittal T2-
weighted image. In (A), (G), and (J), note
the diffuse T2 hyperintense signal of
almost the entire supratentorial white
matter. In subject 1, only the anterior
section of the posterior limb of the inter-
nal capsule and a narrow band of the
subcortical white matter in the occipital
lobe are spared. In all subjects, the superior
(D, H, and K; red arrows) and inferior (E, I,
and L; red arrows) cerebellar peduncles and
the anterior brainstem (D, H, and K; blue
arrows) are affected. In the spinal cord,
the dorsal columns (C and F; blue arrows)
and the lateral corticospinal tracts (F, red
arrow) are hyperintense. We note that
in several individuals, the white-matter
signal on the T2-weighted images was
more elevated than usual for hypomyeli-
nating leukoencephalopathies, similar to
what has recently been described for
another disease, hypomyelination with
congenital cataracts (MIM 610532).2Sanger sequencing. Intriguingly, we noted that recessive
mutations in the DARS mitochondrial paralog, DARS2
(MIM 610956), had been previously associated with
another white-matter disorder, leukoencephalopathy
with brain stem and spinal cord involvement and elevated
lactate (LBSL [MIM 611105]).8
Concurrently, as part of an ongoing study applying MRI
pattern analysis2 to unclassified leukoencephalopathies at
VU University Medical Center (the study was approved by
the VUMC Medical Ethics Committee, and informed con-
sent was obtained from all participating individuals), four
subjects—one pair of brothers and two single unrelated
individuals from consanguineous Indian families—with a
previously undescribed disorder were identified. All had
diffuse hypomyelination of the cerebral white matter and
striking abnormalities of specific brain stem structuresThe American Journal of Huma(Figure 1 and Table S2). In those
subjects who had a spinal MRI,
the dorsal columns also showed
abnormal signal. Clinically, all sub-
jects developed nystagmus in the
first year of life and had severe leg
spasticity and mild cerebellar dys-
function. For identification of the
responsible mutations, WES was
performed on one subject and his
mother and on another unrelated
affected subject. Using the bio-
informatic methods outlined above
and in Table S3, we identified
two homozygous DARS mutations:
subject 2 was homozygous forc.766A>C (p.Met256Leu), and subject 4 was homozygous
for c.1459C>T (p.Arg487Cys) (Figures 1 and 2 and Table 1).
Sanger sequencing confirmed these mutations and
a c.766A>C (p.Met256Leu) homozygous mutation in
subject 2’s affected sibling (subject 3; see Tables 1 and
S1). Both sets of parents were confirmed to be heterozy-
gous carriers.
We then queried two biorepositories, the Centre for
Children with White Matter Disorders and the Myelin
Disorders Bioregistry Project (approved by the VUMC
Medical Ethics Committee and the Children’s National
Medical Center’s Ethics Program, respectively; informed
consent was obtained from all participating individuals),
and identified five more subjects who had the same MRI
pattern and who were all confirmed to have mutations in
DARS (Tables 1 and S1–S4). This included a five-membern Genetics 92, 774–780, May 2, 2013 775
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Figure 2. DARS Mutations in Individuals with HBSL
(A) Genomic organization of DARS in humans (UCSC Genome Browser hg19).
(B)Mutations and their positionswithin theDARS cDNA. Note that all identifiedmutations fall in the 30 end ofDARS, which encodes the
active site of the AspRS. No mutations were detected within the hinge domain or the anticodon-binding domain.
(C) Five DARSmutations affect amino acids that are conserved in S. cerevisiae (Table 1), and the orientation of these amino acids within
the protein can therefore be visualized with the crystal structure of the yeast DARS homolog, DSP1 (Protein Data Bank ID 1ASZ), in
complex with tRNA-Asp. In this image, p.Ala274 (yeast p.Ala327) is shown in red, p.Asp367 (yeast p.Asp421) is shown in green,
p.Pro464 (yeast p.Pro521) is shown in cyan, p.Arg487 (yeast p.Arg543) is shown in orange, and p.Arg494 (p.Arg554) is shown in
magenta. Note that four of the affected amino acids sit within regions that stabilize the tRNA (orange ribbon) in complex with DSP1.
Two alterations, p.Ala274Val and p.Asp367Tyr, sit in the active-site pocket and resulted from a compound-heterozygous mutation in
a single subject (Table 1). An animation of this structure can be found online (DARS animation in Web Resources). Visualization of
the predicted human DARS structure and the HBSL mutations can be found in Figure S1.family that had been analyzed by ultra-high-coverage
exome sequencing, which revealed a compound-heterozy-
gous DARS mutation in two affected sisters (subjects 6
and 7; Tables 1 and S1–S4); this mutation was absent
from their unaffected sibling. Taken together, these find-
ings demonstrate that a previously uncharacterized
leukoencephalopathy characterized by hypomyelination
with brain stem and spinal cord abnormalities and leg
spasticity (HBSL) is caused by recessive mutations in DARS.
To evaluate the potential effects of these DARS muta-
tions, we assessed their relative incidence, conservation,
and predicted pathogenicity (Table 1). Five were absent
from SNPdb 135, the 1000 Genomes Project databases,
and the National Heart, Lung, and Blood Institute (NHBLI)
Exome Sequencing Project Exome Variant Server
(ESP6500SI release), and the remaining three had minor
allele frequencies of ~0.001 (Table 1). All are conserved in
the C. elegans DARS ortholog, drs-1, and five are conserved
in the S. cerevisiae ortholog, DPS1. AspRS DARS is a funda-
mental component of the translational machinery, and a
wide range of previous studies have shown that loss of
AspRS activity in Drosophila and yeast is lethal (reviewed
in Table S5) and that selective knockdown of AspRS in
Drosophila neuroblasts leads to shorter lineages, alterations776 The American Journal of Human Genetics 92, 774–780, May 2, 2to cell shape, and defects in the ganglion mother cell.9
Consistentwith these reports, we found thatwhen assessed
with a combination of six damage-prediction algorithms,
all the HBSL DARSmutations were classified as pathogenic
by at least two independent metrics (Table S4), strongly
suggesting that these variants are the cause of HBSL.
The mutations identified in this study lie in the 30 third
of DARS, the region which corresponds to the C-terminal
active-site domain of DARS. Two previous site-directed-
mutagenesis studies in yeast have shown that alteration
of any of the amino acids that reside within the active site’s
hydrogen-bond network or the nearby side chains is
detrimental to the enzyme10 and that any alteration in
the C-terminal lobe of the protein leads to a minimum
3-fold reduction of enzyme activity.11 To investigate how
the mutations identified in this study might affect DARS
activity, we mapped each affected amino acid to a
predicted human DARS crystal structure (Figure S1) and
all the highly conserved amino acids to the yeast DPS1
crystal structure (Figure 2). Strikingly, we found that two
mutations alter amino acids that sit within the active-site
pocket (p.Ala274Val and p.Asp367Tyr from subject 1),
three alter amino acids that are likely to destabilize the
tRNA-protein interaction (p.Arg487Cys, p.Arg494Cys,013









Alteration Inheritance Frequencyb dbSNP ID Conservationc
Damage
Predictiond
1 Australia chr2: 136,673,803 c.1099G>T 11 p.Asp367Tyr paternal 0% - S. cerevisiae damaging





chr2: 136,680,399 c.766A>C 9 p.Met256Leu homozygous 0% - C. elegans damaging
4 India chr2: 136,664,933 c.1459C>T 16 p.Arg487Cys homozygous 0% - S. cerevisiae damaging
6,e 7e USA chr2: 136,668,744 c.1379G>A 15 p.Arg460His paternal 0% - C. elegans damaging
chr2: 136,664,912 c.1480C>T 16 p.Arg494Gly maternal 0.001% rs147077598 S. cerevisiae damaging
9,e 10e UK chr2: 136,668,733 c.1391C>T 15 p.Pro464Leu ND 0.0018%f rs148806569 C. elegans damaging
chr2: 136,664,912 c.1480C>T 16 p.Arg494Cys ND 0% - S. cerevisiae damaging
The following abbreviation is used: ND, not determined.
aDARS RefSeq NM_001349.2.
bFrequency of occurrence according to the ESP6500SI release of the NHBLI Exome Variant Server (see Web Resources).
cConservation was analyzed in 11 species, including human, chimp, rhesus, mouse, chicken, frog, zebrafish, tetraodon, Drosophila, C. elegans, and S. cerevisiae.
dPlease see Table S4 for damage scores from six damage prediction algorithms.
eSibling pairs are as follows: 2 and 3, 6 and 7, and 9 and 10.
fFrequency specifically within the Africa-American (AA) ESP6500SI population.and p.Arg494Gly), and the remaining mutations alter
amino acids that are likely to be fundamental to chains
supporting the active site (Figure 2 and Figure S1).
To gain further insight into the pathogenic role of these
mutations in HBSL, we performed an investigation of
DARS expression in humans and mice by using a curated
set of publicly available data. Consistent with the fact
that DARS is a core component of the translational
machinery, we found that it is diffusely localized in cyto-
plasm and broadly expressed across tissue types (by both
RNA-seq and array-based measures of expression), includ-
ing the central nervous system (Figures S2 and S3). In
mice, Dars shows specific expression in sagittal brain sec-
tions with staining in the hippocampus, the dentate gyrus,
and the molecular layer of the cerebellum, which is strik-
ingly similar to the expression patterns of glycyl-tRNA syn-
thetase (Gars) and lysyl-tRNA synthetase (Kars), but shows
little overlap with glial and oligodendrocyte markers
(Figure S4). For example, Dars, Kars, and Gars are clearly
expressed in the cerebellar molecular layer (which houses
Purkinje neurons), whereas the oligodendrocyte markers
Mog, CNPase, and Olig2 are highly expressed in the gran-
ular layer (Figure S4). DARS expression in the developing
and adult human brain shows similar patterns—it is highly
expressed in the ventricular and subventricular zones,
including hippocampal subfields, the midlateral temporal
cortex, and the frontal polar cortex (Figure S5). Likewise,
DARS immunostaining of the cerebellum, cerebral cortex,
hippocampus, and lateral ventricle all show preferential
neuronal staining, and staining of peripheral neurons is
evident in the colon (Figure S6). Overall, these data are
consistent with HBSL’s clinical presentation.
It is becoming increasingly apparent that mutations in
genes encoding both cytoplasmic and mitochondrial
tRNA synthetases (ARSs) can cause a wide range of neuro-The Amlogical and multisystem disorders (reviewed in Table 2).
For example, leukoencephalopathy with thalamus and
brain stem involvement and high lactate (LTBL) is caused
by mutations in EARS29 (MIM 612799), encoding a
mitochondrial tRNA synthetase, and several forms of
Charcot-Marie-Tooth disease (CMT [MIM 613287,
601472, 608323, and 613641]), a peripheral neuropathy,
are caused by damaging mutations in AARS (MIM
601065), GARS (MIM 600287), YARS (MIM 603623), and
KARS (MIM 601421) (Table 2), encoding cytoplasmic
aminoacyl-tRNA synthetases. Similarly, recessive muta-
tions in DARS2, encoding the mitochondria-specific
aspartyl-tRNA synthetase, cause LBSL.8
Intriguingly, despite the fact that DARS and DARS2 have
mutually exclusive subcellular localizations (Table 2), LBSL
and HBSL are strikingly similar in their presentation. For
example, they both manifest with abnormalities in the
same central nervous system structures, including the
superior and inferior cerebellar peduncles, the medial
lemniscus and pyramidal tracts in the brain stem and the
dorsal columns, and the lateral corticospinal tracts in the
spinal cord—structures that are rarely affected in other
leukoencephalopathies and the combination of which
appears to be unique to HBSL and LBSL. The similarity in
MRI abnormalities is such that one of the individuals
(subject 7) had been initially classified as ‘‘variant LBSL’’
(Figure S7). Consistent with other reports,10 we find it
unlikely that HBSL and LBSL are caused by amino acid
mischarging alone (although this might be an important
factor). Indeed, recent work has demonstrated that muta-
tions in DARS2 decrease catalytic activity by impairing
dimer formation or by reducing protein expression27,28
but that activity of the respiratory chain is normal in indi-
viduals with LBSL.8 Many ARSs are known to have alterna-
tive functions beyond translation,29 including AspRS,erican Journal of Human Genetics 92, 774–780, May 2, 2013 777
Table 2. Disease-Associated Genes Encoding tRNA Synthetases
Gene Gene MIM
Cognate
Amino Acid Localization Disease Hallmarks Phenotype MIM Inheritance Reference
AARS 601065 alanine C CMT 2N axonal neuropathy 613287 AD Latour et al.12
AARS2 612035 alanine M combined oxidative phosphorylation
deficiency 8
muscular hypotonia, fatal hypertrophic
cardiac myopathy
614096 AR Gotz et al.13
DARS 603084 aspartate C HBSL leukoencephalopathy (hypomyelination)
with brain stem and spinal cord involvement
- AR this study
DARS2 610956 aspartate M LBSL leukoencephalopathy with brain stem and
spinal cord involvement and elevated lactate
611105 AR Scheper et al.8
EARS2 612799 glutamine M LTBL leukoencephalopathy with thalamic and
brain stem involvement and elevated lactate
614924 AR Steenweg et al.14
FARS2 611592 phenylalanine M combined oxidative phosphorylation
deficiency 14
neonatal encephalopathy with seizures and
liver involvement
614946 AR Elo et al.15 and
Shamseldin et al.16
GARS 600287 glycine C CMT 2D; distal hereditary motor
neuropaty type V
axonal neuropathy 601472 and 600794 AD Antonellis et al.17
HARS 142810 histidine C Usher syndrome type 3B retinitis pigmentosa, sensorineural deafness,
ataxia
614504 AR Puffenberger et al.18
HARS2 600783 histidine M Perrault syndrome 2 sensorineural deafness, primary amenorrhea,
ovarian dysgenesis
614926 AR Pierce et al.19
KARS 601421 lysine C recessive intermediate CMT neuropathy with axonal and demyelinating
features
613641 AR McLaughlin et al.20
LARS2 604544 leucine M Perrault syndrome sensorineural deafness, premature ovarian
failure
- AR Pierce et al.21
MARS2 609728 methionine M spastic ataxia 3 autosomal-recessive spastic ataxia with
leukoencephalopathy (arsal)
611390 AR Bayat et al.22
RARS2 611524 arginine M pontocerebellar hypoplasia type 6 pontocerebellar and cerebellar atrophy,
epilepsy
611523 AR Edvardson et al.23
SARS2 612804 serine M hyperuricemia, pulmonary hypertension,
renal failure, and alkalosis
renal failure in infancy, metabolic alkalosis,
pulmonary hypertension
613845 AR Belostotsky et al.24
YARS 603623 tyrosine C dominant intermediate CMT neuropathy with axonal and demyelinating
features
608323 AD Jordanova et al.25
YARS2 610957 tyrosine M mitochondrial myopathy sideroblastic anemia and myopathy with
exercise intolerance
613561 AR Riley et al.26

















































which is involved in asparagine biosynthesis.30 This
suggests that the disease etiology and progression of
HBSL and LBSL, and possibly other ARS-associated
illnesses, might be driven by processes and biological
relationships that are not yet fully understood.Supplemental Data
Supplemental Data include seven figures and five tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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